---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-050775"
form_type: "8-K"
ticker: "MDGL"
cik: "0001157601"
company_name: "MADRIGAL PHARMACEUTICALS, INC."
filed_at: "2026-07-30T11:03:02+00:00"
generated_at: "2026-07-30T11:05:50.400510+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Madrigal Q2 Rezdiffra sales $364.3M (+71% YoY); net loss $57.9M

## Summary
- Rezdiffra net sales $364.3M, up 71% from $212.8M in Q2 2025; over 49,000 patients on therapy as of June 30, 2026.
- Net loss $57.9M ($1.99/share) vs. $42.3M ($1.50/share) a year ago; includes $25M one-time business development expense.
- Cash and marketable securities $838.9M as of June 30, 2026, down from $988.6M at Dec. 31, 2025.
- Three new resmetirom patents issued, including one for F4c (well-compensated cirrhosis) with protection into 2042.
- MGL-2086 (oral GLP-1) Phase 1 SAD trial initiated in June 2026 for Rezdiffra combination program in MASH.

## SEC filing metadata
- accession: 0001628280-26-050775
- form_type: 8-K
- ticker: MDGL
- cik: 0001157601
- company_name: MADRIGAL PHARMACEUTICALS, INC.
- filed_at: 2026-07-30T11:03:02+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/0001628280-26-050775-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/mdgl-20260730.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-050775
- JSON: https://secwatch.observer/filing/0001628280-26-050775.json
- Plain text: https://secwatch.observer/filing/0001628280-26-050775.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.